Detection of Cancer Stem Cells Using AC133 Antibody

  • Veronica Catalano
  • Antonina Benfante
  • Pietro Mancuso
  • Francesco Dieli
  • Giorgio Stassi
  • Matilde Todaro
Chapter
Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 5)

Abstract

The cancer stem cell (CSC) model postulates that tumors are formed and maintained by a small population of undifferentiated cells, characterized by unique self-renewal properties and malignant potential. As CSCs survive chemotherapy inducing tumor recurrence, the specific targeting and eradication of these cells represents an important therapeutic challenge in cancer cure. Recent findings on CD133, a pentaspan transmembrane glycoprotein, discuss its application in the identification and isolation of SCs from cancerous tissues. However, the appropriateness of this protein constitutes an ongoing discussion. The expression pattern is debated and several issues highlight the need for additional surface molecules or alternative methods to identify tumor-initiating cells. In this chapter, we will critically summarize progresses and concerns for targeting CSCs via this marker.

Keywords

Cancer Stem Cell Stem Cell Marker Cancer Stem Cell Phenotype Brain Tumor Stem Cell Colorectal Cancer Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18:460–466PubMedCrossRefGoogle Scholar
  2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988PubMedCrossRefGoogle Scholar
  3. Bidlingmaier S, Zhu X, Liu B (2008) The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 86:1025–1032PubMedCrossRefGoogle Scholar
  4. Campos B, Herold-Mende CC (2011) Insight into the complex regulation of CD133 in glioma. Int J Cancer 128:501–510PubMedCrossRefGoogle Scholar
  5. Cheng JX, Liu BL, Zhang X (2009) How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 35:403–408PubMedCrossRefGoogle Scholar
  6. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951PubMedCrossRefGoogle Scholar
  7. Corbeil D, Fargeas C, Huttner W (2001a) Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein. Biochem Biophys Res Commun 285:939–944PubMedCrossRefGoogle Scholar
  8. Corbeil D, Röper K, Fargeas CA, Joester A, Huttner WB (2001b) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2:82–91PubMedCrossRefGoogle Scholar
  9. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158–10163PubMedCrossRefGoogle Scholar
  10. Deonarain MP, Kousparou CA, Epenetos AA (2009) Antibodies targeting cancer stem cells. MAbs 1:12–25PubMedCrossRefGoogle Scholar
  11. Dirks PB (2008) Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philos Trans R Soc Lond B Biol Sci 363:139–152PubMedCrossRefGoogle Scholar
  12. Fabrizi E, di Martino S, Pelacchi F, Ricci-Vitiani L (2010) Therapeutic implications of colon cancer stem cells. World J Gastroenterol 16:3871–3877PubMedCrossRefGoogle Scholar
  13. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, Gillespie GY (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3:e3655PubMedCrossRefGoogle Scholar
  14. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323PubMedCrossRefGoogle Scholar
  15. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382–3389PubMedCrossRefGoogle Scholar
  16. Jászai J, Janich P, Farkas LM, Fargeas CA, Huttner WB, Corbeil D (2007) Differential expression of Prominin-1 (CD133) and Prominin-2 in major cephalic exocrine glands of adult mice. Histochem Cell Biol 128:409–419PubMedCrossRefGoogle Scholar
  17. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP (2010) The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70:719–729PubMedCrossRefGoogle Scholar
  18. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037PubMedCrossRefGoogle Scholar
  19. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021PubMedGoogle Scholar
  20. O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110PubMedCrossRefGoogle Scholar
  21. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood 95:952–958PubMedGoogle Scholar
  22. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115PubMedCrossRefGoogle Scholar
  23. Ricci-Vitiani L, Pallini R, Larocca LM, Lombardi DG, Signore M, Pierconti F, Petrucci G, Montano N, Maira G, De Maria R (2008) Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ 15:1491–1498PubMedCrossRefGoogle Scholar
  24. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R (2009) Colon cancer stem cells. J Mol Med 87:1097–1104PubMedCrossRefGoogle Scholar
  25. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824–828PubMedCrossRefGoogle Scholar
  26. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D’Angelica M, Kemeny N, Lyden D, Rafii S (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120PubMedGoogle Scholar
  27. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401PubMedCrossRefGoogle Scholar
  28. Taïeb N, Maresca M, Guo XJ, Garmy N, Fantini J, Yahi N (2009) The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett 278:164–173PubMedCrossRefGoogle Scholar
  29. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1:389–402PubMedCrossRefGoogle Scholar
  30. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R, Stassi G (2010) Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 70:8874–8885PubMedCrossRefGoogle Scholar
  31. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP (2008) Cancer stem cells-old concepts, new insights. Cell Death Differ 15:947–958PubMedCrossRefGoogle Scholar
  32. Weigmann A, Corbeil D, Hellwig A, Huttner WB (1997) Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-­epithelial cells. Proc Natl Acad Sci USA 94:12425–12430PubMedCrossRefGoogle Scholar
  33. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Veronica Catalano
    • 1
  • Antonina Benfante
    • 1
  • Pietro Mancuso
    • 1
  • Francesco Dieli
    • 1
  • Giorgio Stassi
    • 1
  • Matilde Todaro
    • 1
  1. 1.Laboratory of Cellular and Molecular Pathophysiology, Department of Surgical and Oncological SciencesUniversity of PalermoPalermoItaly

Personalised recommendations